Health Care & Life Sciences » Pharmaceuticals | Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Cipher Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Grandeur Peak International Opportunities Fund
742,300
2.78%
-11,200
0.23%
04/30/2018
Grandeur Peak Global Opportunities Fund
588,400
2.2%
-20,800
0.2%
04/30/2018
Taylor North American Equity Opportunities Fund
243,100
0.91%
0
3.12%
06/30/2017
SEI Investments - Canadian Equity Fund
186,886
0.7%
0
0.03%
12/31/2017
Grandeur Peak Global Reach Fund
160,200
0.6%
0
0.11%
04/30/2018
SEI Investments - Canadian Small Company Equity Fund
130,856
0.49%
0
0.21%
12/31/2017
31,300
0.12%
0
0.2%
04/30/2018
Marquis Institutional Canadian Equity Portfolio
20,597
0.08%
-94
0.06%
12/31/2017
Voya Multi Manager International Small Cap Fund
9,093
0.03%
0
0.01%
06/30/2018
Norrep Entrepreneurs Class
0
0%
-22,700
0%
04/30/2018

About Cipher Pharmaceuticals

View Profile
Address
209 Oak Park Boulevard
Oakville Ontario L6H 0M2
Canada
Employees -
Website http://www.cipherpharma.com
Updated 07/08/2019
Cipher Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the robust and diversified portfolio of commercial and late-stage products. It also acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly or through partners. Its products include Actikerall, Aclaro, Beteflam, Epuris, Vaniqa, Dermadexin, Pruridexin, Ozenoxacin, Lipofen, Conzip, and Durela.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.